United States: Sunil Aggarwal, PhD – Removal of Cannabis from Schedule I of the Controlled Substances Act
The Pharmaceuticalization of Cannabis: Rescheduling proponents suggest cannabis doesn't meet the Controlled Substances Act's extensive criteria for placement in Schedule I. The U.S. Government clings to the stance that cannabis merit’s Schedule I status.
By Michael Bachara, Hemp News Correspondent
Sunil Aggarwal, PhD, represents a new generation of scientific-minded doctors, leaving cannabis’ negative propaganda behind and fighting for it as a valuable, medicinal plant. His credentials include the Medical and Scientific Advisory Board of Americans for Safe Access (ASA), Health Professionals for Responsible Drug Scheduling, service on the Board of Directors for the American Academy of Cannabinoid Medicine and he is a Seattle Hempfest Core Staff Member.
In these videos, Aggarwal gives a brief overview of the corrupt pharmaceutical influence taking place within the United States and the urgency for the Obama Administration to remove cannabis as a Schedule I substance so it may be allowed to enhance the lives of patients without being turned into a pharmaceutical extract, padding the pockets of corporate investors in order to satisfy their economic bottom-line.
According to their website, the group “Health Professionals for Responsible Drug Scheduling” is examining irresponsible drug scheduling that the government has continually maintained for naturally occurring drugs or substances. These schedules will be challenged on scientific and humanitarian grounds, drawing on the accumulated wealth of knowledge about these drugs and their uses gathered from all fields. Regarding the schedule designations for substances which are judged to be unscientific and unjust, an advocacy and public education for their responsible rescheduling will be undertaken. The group envisions future scenarios of health and social development that would be possible with responsible drug scheduling.
The group is open to all health professionals and health scientists, including those retired and in-training. Non-health professionals can also join as supporters. Get involved in the growing online group to bring awareness to this matter.
In 2009, Aggarwal was awarded the Oregon NORML Rick Bayer Award for his courage to speak out effectively and elevate the conscientiousness in American medicine to reconsider cannabis as a viable medicine for future generations to study.
• Filing of Petition with DEA
• Acceptance of Petition by DEA
• Initial Review by DEA
• Referral to HHS
• Scientific and Medical Evaluation by HHS
• HHS Report to DEA
• Evaluation of Additional Information by DEA
• Publication of DEA Decision
• (Judicial review by the U.S. Court of Appeals)
• (Public Hearing on Disputed Matters of Fact)